Free Trial
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

Arcus Biosciences logo
$14.70 +0.42 (+2.94%)
(As of 11/22/2024 ET)

About Arcus Biosciences Stock (NYSE:RCUS)

Key Stats

Today's Range
$14.20
$15.07
50-Day Range
$14.30
$18.44
52-Week Range
$13.49
$20.31
Volume
534,330 shs
Average Volume
788,277 shs
Market Capitalization
$1.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00
Consensus Rating
Buy

Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
55th Percentile Overall Score

RCUS MarketRank™: 

Arcus Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 512th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Arcus Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arcus Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.20) to ($4.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcus Biosciences is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcus Biosciences is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcus Biosciences has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Arcus Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.82% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently increased by 4.89%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Arcus Biosciences does not currently pay a dividend.

  • Dividend Growth

    Arcus Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.82% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently increased by 4.89%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Arcus Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcus Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcus Biosciences' insider trading history.
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Stock News Headlines

2025: Digital Asset Insights You Need to Know
Cryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.
Arcus Biosciences Reports Q3 2024 Results
See More Headlines

RCUS Stock Analysis - Frequently Asked Questions

Arcus Biosciences' stock was trading at $19.10 on January 1st, 2024. Since then, RCUS stock has decreased by 23.0% and is now trading at $14.70.
View the best growth stocks for 2024 here
.

Arcus Biosciences, Inc. (NYSE:RCUS) released its earnings results on Wednesday, November, 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.06. The business's revenue was up 50.0% on a year-over-year basis.

Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences' top institutional shareholders include FMR LLC (4.88%), State Street Corp (3.29%), Point72 Asset Management L.P. (2.66%) and Geode Capital Management LLC (1.34%). Insiders that own company stock include Gilead Sciences, Inc, Juan C Jaen, Terry J Rosen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang and Alexander Azoy.
View institutional ownership trends
.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/06/2024
Today
11/22/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/19/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.00
High Stock Price Target
$44.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+131.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-307,000,000.00
Net Margins
-102.66%
Pretax Margin
-102.28%

Debt

Sales & Book Value

Annual Sales
$263 million
Book Value
$6.17 per share

Miscellaneous

Free Float
80,256,000
Market Cap
$1.35 billion
Optionable
Optionable
Beta
0.89
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NYSE:RCUS) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners